Prescription RequiredTUCATINIB 150 mg (Tukavo) is a prescription targeted anticancer medicine used to treat HER2-positive breast cancer and HER2-positive colorectal cancer in combination with other anticancer therapies. It belongs to a class of medicines called HER2 tyrosine kinase inhibitors (TKIs) and works by blocking HER2 signalling pathways that promote cancer-cell growth. It should be used only under the supervision of an oncologist.
| Generic name | TUCATINIB |
| Strength | 150 mg |
| Manufacturer | Zydus |
| Package size | 60 Tablets |
| Used for | Advanced HER2-positive breast cancer and RAS wild-type colorectal cancer |
| Availability | In Stock |
| Shipping to | USA, UK, Australia, Canada, New Zealand, Philippines, Tunisia, France, Italy, South Korea, Albania, Romania, Hong Kong, Malaysia, Thailand, Singapore, UAE, Georgia, Armenia, Saudi Arabia, Qatar, Kuwait, South Africa, and many other countries. |
Tucatinib 150 mg works by selectively blocking the HER2 tyrosine kinase enzyme, which plays an important role in cancer-cell growth and survival. By inhibiting HER2 signalling, tucatinib reduces the ability of HER2-positive cancer cells to grow, multiply, and spread, helping slow tumour progression.
Dr. Neeru Mehta holds a Doctor of Medicine (MD) degree and has a professional interest in oncology and cancer care. Her interests include cancer treatments, monitoring treatment progress, managing side effects and supportive care.
